Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022

Euro Surveill. 2022 Sep;27(39):2200701. doi: 10.2807/1560-7917.ES.2022.27.39.2200701.

Abstract

We assess the immunogenicity and efficacy of Spikevax and Comirnaty as fourth dose COVID-19 vaccines. Six months post-fourth-dose, IgG levels were higher than pre-fourth dose at 1.58-fold (95% CI: 1.27-1.97) in Spikevax and 1.16-fold (95% CI: 0.98-1.37) in Comirnaty vaccinees. Nearly 60% (159/274) of vaccinees contracted SARS-CoV-2. Infection hazard ratios (HRs) for Spikevax (0.82; 95% CI: 0.62-1.09) and Comirnaty (0.86; 95% CI: 0.65-1.13) vaccinees were similar, as were substantial-disease HRs, i.e. 0.28 (95% CI: 0.13-0.62) and 0.51 (95% CI: 0.27-0.96), respectively.

Keywords: BNT162b2; COVID-19; boosters; immunogenicity; mRNA1273; vaccine efficacy.

MeSH terms

  • COVID-19 Vaccines*
  • COVID-19* / prevention & control
  • Follow-Up Studies
  • Humans
  • Immunoglobulin G
  • Israel / epidemiology
  • RNA, Messenger
  • SARS-CoV-2 / genetics

Substances

  • COVID-19 Vaccines
  • Immunoglobulin G
  • RNA, Messenger